期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 6, 期 3, 页码 219-230出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1083-8791(00)70004-8
关键词
varicella-zoster virus; hematopoietic cell transplantation; latency; immunosuppression
资金
- NCI NIH HHS [P01-CA49605] Funding Source: Medline
- NIAID NIH HHS [AI36884, AI20459] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P01CA049605] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036884, R21AI036884, R01AI020459] Funding Source: NIH RePORTER
New information about the mechanisms of varicella-zoster virus (VZV) pathogenesis and the host response to the virus has improved our understanding of the threat that VZV reactivation may pose after hematopoietic cell transplantation (HCT). Antiviral therapy compensates for some of the deficiencies in VZV immunity in HCT recipients, and inactivated varicella vaccine may be useful for the early reconstitution of adaptive immunity to VZV after HCT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
